Update on the Combination of Myo-Inositol/D-Chiro-Inositol for the Treatment of Polycystic Ovary Syndrome

The review examines the use of myo-inositol (MYO) and D-chiro-inositol (DCI) for treating polycystic ovary syndrome (PCOS), finding that MYO alone and in combination with DCI at a 40:1 ratio are effective, particularly for improving insulin sensitivity, ovulatory function, and oocyte quality. A meta-analysis of nine clinical trials involving 247 PCOS patients supports the efficacy and safety of these treatments compared to traditional options like metformin. The review suggests that while the 40:1 ratio is effective, further research into higher MYO ratios, such as 66:1 to 100:1, could enhance treatment outcomes. Maintaining a proper inositol ratio is crucial, as higher DCI concentrations can negatively impact reproductive outcomes.